Quarterly report pursuant to Section 13 or 15(d)

Collaboration Agreements and Supply Agreements (Tables)

v3.10.0.1
Collaboration Agreements and Supply Agreements (Tables)
9 Months Ended
Sep. 30, 2018
Collaboration Agreements And Supply Agreements [Abstract]  
Summary of Recognized Revenue

The Company has recognized revenue as follows:

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2018

 

 

2017

 

 

2018

 

 

2017

 

 

 

(in thousands)

 

 

(in thousands)

 

Collaboration revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Celgene Corporation (“Celgene”)—related party:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of up-front payment

 

$

1,655

 

 

$

2,642

 

 

$

4,912

 

 

$

16,355

 

Research and development services

 

 

5

 

 

 

 

 

 

103

 

 

 

 

Milestones and contingent payments

 

 

 

 

 

13,112

 

 

 

 

 

 

 

25,937

 

Total

 

 

1,660

 

 

 

15,754

 

 

 

5,015

 

 

 

42,292

 

Merck Sharp & Dohme Corporation (“Merck”)—related party:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of up-front payment

 

 

2,818

 

 

 

 

 

 

2,818

 

 

 

 

Research and development services

 

 

696

 

 

 

 

 

 

696

 

 

 

 

Total

 

 

3,514

 

 

 

 

 

 

3,514

 

 

 

 

Merck KGaA, Darmstadt, Germany (operating in the United

   States and Canada under the name “EMD Serono”):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of up-front payment

 

 

1,038

 

 

 

1,030

 

 

 

3,104

 

 

 

3,090

 

Research and development services

 

 

712

 

 

 

715

 

 

 

2,322

 

 

 

2,319

 

Total

 

 

1,750

 

 

 

1,745

 

 

 

5,426

 

 

 

5,409

 

Total collaboration revenue

 

$

6,924

 

 

$

17,499

 

 

$

13,955

 

 

$

47,701

 

Other revenue—related parties:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Celgene Corporation:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Development and manufacturing services and clinical

   product supply

 

$

330

 

 

$

 

 

$

3,894

 

 

$

 

SutroVax:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Supply and other

 

 

582

 

 

 

 

 

 

1,484

 

 

 

 

Total other revenue—related parties

 

$

912

 

 

$

 

 

$

5,378

 

 

$

 

Total revenue

 

$

7,836

 

 

$

17,499

 

 

$

19,333

 

 

$

47,701